First Commonwealth Earnings Preview

First Commonwealth (NYSE:FCF) is set to give its latest quarterly earnings report on Tuesday, 2023-04-25. Here’s what investors…

First Commonwealth (NYSE:FCF) is set to give its latest quarterly earnings report on Tuesday, 2023-04-25. Here’s what investors need to know before the announcement.

Analysts estimate that First Commonwealth will report an earnings per share (EPS) of $0.39.

First Commonwealth bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.04, which was followed by a 7.12% drop in the share price the next day.

Here’s a look at First Commonwealth’s past performance and the resulting price change:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 0.43 0.38 0.33 0.30
EPS Actual 0.39 0.37 0.33 0.29
Price Change % -7.12% -2.66% 2.9% 0.0%

eps graph

Stock Performance

Shares of First Commonwealth were trading at $11.85 as of April 21. Over the last 52-week period, shares are down 14.1%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

To track all earnings releases for First Commonwealth visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB